Search Results
Showing 10 of 4,265 search results for:
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 1 of 10
Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 2 of 10
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 3 of 10
Therapy for Children With Advanced Stage Neuroblastoma
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 4 of 10
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 5 of 10
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 6 of 10
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Status
Condition
Smoldering Plasma Cell Myeloma, Light Chain Deposition Disease
Phase
INTERVENTION
Other: Clinical Observation, Drug: Lenalidomide
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 7 of 10
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Drug: RP followed by MPR
Eligibility
Ages Eligible for Study : 65 Years and older (Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 8 of 10
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Status
Condition
CLL (Chronic Lymphocytic Leukemia), Small Lymphocytic Lymphoma
Phase
INTERVENTION
Drug: Fludarabine Phosphate, Biological: Ofatumumab, Drug: Cyclophosphamide
Eligibility
Ages Eligible for Study : 18 to 99 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 9 of 10
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Status
Condition
Not provided
Phase
INTERVENTION
Not provided
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 10 of 10